Thyroxine softgel capsule in patients with gastric-related T4malabsorption

التفاصيل البيبلوغرافية
العنوان: Thyroxine softgel capsule in patients with gastric-related T4malabsorption
المؤلفون: Santaguida, Maria, Virili, Camilla, Duca, Susanna, Cellini, Miriam, Gatto, Ilenia, Brusca, Nunzia, Vito, Corrado, Gargano, Lucilla, Centanni, Marco
المصدر: Endocrine; May 2015, Vol. 49 Issue: 1 p51-57, 7p
مستخلص: The key role of an intact gastric acid secretion for subsequent intestinal T4absorption is supported by an increased requirement of thyroxine in patients with gastric disorders. A better pH-related dissolution profile has been described in vitro for softgel T4preparation than for T4tablets. Our study was aimed at comparing softgel and tablet T4requirements in patients with gastric disorders. A total of 37 patients with gastric-related T4malabsorption were enrolled, but only 31 (28F/3M; median age = 50 years; median T4dose = 2.04 μg/kg/day) completed the study. All patients were in long-lasting treatment (>2 years) with the same dose of T4tablets when treatment was switched to a lower dose of softgel T4capsules (−17 %; p= 0.0002). Assessment of serum FT4and TSH was carried out at baseline and after 3, 6, 12, and 18 months after the treatment switch. In more than 2/3 of patients (good-responders n= 21), despite the reduced dose of T4, median TSH values were similar at each time point (p= 0.3934) with no change in FT4levels. In the remaining patients (poor-responders n= 10), TSH levels were significantly higher at each time point than at baseline (p< 0.0001). To note, in five of them intestinal comorbidity was subsequently detected. Comorbidity associated with poor-responders status was the only significant predictor in multivariate analysis (OR = 11.333). Doses of softgel T4capsules lower than T4tablet preparation are required to maintain the therapeutic goal in 2/3 of patients with impaired gastric acid secretion.
قاعدة البيانات: Supplemental Index
الوصف
تدمد:1355008x
15590100
DOI:10.1007/s12020-014-0476-7